












Supplementary Information

The tumor suppressor TMEM127 regulates insulin sensitivity in a tissue-specific manner

Srikantan et al.

A**B****C****D****E****F****G****H****I****J****K**

Supplementary Fig 1. Global deletion of Tmem127 impairs growth and results in low adiposity

A) TMEM127 expression in different human tissues by RNA seq from the GTEX project (ENSG00000135956.4, data represent Log10 transformed TPM(transcript per million)+1 values; plots show median and 25th and 75th percentiles, points are outliers (above 1.5x the interquartile range), obtained from the GTEX portal, V7 release (including 11,688 samples from 714 donors) on 06/12/2019); B) Relative Tmem127 expression in tissues from WT and Tmem127 KO mice (n=7 and 12 per genotype, respectively), measured by RT-PCR and normalized to the Tfib gene expression; C) Body weight of female wild-type (WT) and Tmem127 knockout (KO) mice (n=8 and 10 per genotype, respectively) from 6-22 months of age; D) fat and lean mass of male WT and KO mice at the indicated ages (n=5-14 per genotype, respectively); E) fat mass/lean mass ratio of female WT and KO mice across ages (n=8 or 10 per genotype, respectively); F) Plasma levels of norepinephrine and epinephrine of adult male WT (n=6) and KO (n=7) mice measured by gas chromatography/mass spectrometry (GC/MS); G) Western blot of adrenal lysates of WT and KO adult male mice (n=4 per genotype), probed for mTORC1 targets S6K (phosphorylated S6K, pS6K and total S6K) and p-4EBP1; TMEM127 and loading control antibodies; H) Plasma levels of Fgf21 of adult male WT and KO mice under regular fed conditions, after 24 h fasting and after 4h refeeding (n=6 per genotype); I) Relative inguinal (iWAT), epididymal (eWAT) and brown adipose tissue (BAT) mRNA expression of the Ucp1 gene expression in adult WT and KO mice (n=10 or 12 per genotype, respectively) measured by real-time PCR (RT-PCR) and normalized to Tfllb gene; J) Representative HE-stained sections of inguinal WAT of adult male WT and KO mice (scale bar is 100μM); K) Diameter of the designated adipocytes from adult male WT and KO mice (n=6 per genotype). Data were analyzed by Student's t-test. Values are expressed as mean +/- s.e.m. *P<0.05; **P<0.01; ***P<0.001. Adult mice were 9-12months of age. Source data are provided as a Source Data file.

Supplementary Table 1. Pre-birth and neonatal *Tmem127* knockout mouse fitness based on genotype distribution


Age	Total number of litters	Total number of embryos	KOs (n)	Hets (n)	WT (n)	P value
E13.5	44	299	78	137	84	0.66
E18/E19	9	70	21	30	19	0.63
P0	23	154	27	95	32	0.03

E=embryonic day; P=postnatal day; KO=knockout; WT=wild-type; Hets= heterozygotes; p-value: Z-statistic, significance level

Supplementary Table 2. Perinatal (pre- and post-birth) body weight of *Tmem127* knockout mice

Age	KO			WT				p value
	mean (g)	SEM	n	mean (g)	SEM	n		
E18.5	1.00	0.06	8	1.02	0.07	8	0.55	
P7	3.28	0.21	10	3.79	0.12	18	0.03	
P14	5.22	0.26	10	6.24	0.17	18	0.00	
P21	6.60	0.47	10	8.85	0.20	18	< 0.0001	
P30	11.48	1.00	9	15.77	0.34	16	< 0.0001	
P45	17.00	0.75	7	21.48	0.35	15	< 0.0001	
P60	20.19	0.99	5	24.57	0.37	14	< 0.0001	

E=embryonic day; P=postnatal day; E=embryonic day; P=postnatal day; KO=knockout; WT=wild-type; Hets=heterozygotes; SEM=standard error of the means; p-value: Student's t-test








B

Plasma triglycerides



C

Plasma FFA


Supplementary Fig 2. **Global Tmem127 deletion impairs hepatic lipogenesis.** A) Relative eWAT mRNA expression of the indicated fatty acid synthesis, storage, oxidation and transport gene expression in adult WT and KO mice (n=10 or 12 per genotype, respectively) measured by real-time PCR (RT-PCR) and normalized to TfIib gene; B) Plasma triglyceride content in fed adult WT and KO mice (n=5 per genotype); C) Plasma free fatty acids in fed adult WT and KO mice (n=13 per genotype). Data were analyzed by Student's t-test. Values are expressed as mean +/- s.e.m. *P<0.05; **P<0.01; ***P<0.001. Adult mice were 9-12months of age. Source data are provided as a Source Data file.

A**B****C****D****E**




Supplementary Fig 3. Tmem127 deletion leads to hypoinsulinemia and improved insulin tolerance. A) Blood glucose levels from the GSIS test from Fig 2D-performed in adult male WT and KO mice (n=4 per genotype; B) Fasting (6 hours) blood glucose of 3-6 month-old (young) WT and Tmem127 KO male mice (n=37 and 24 per genotype, respectively); C) Fasting (6 hours) serum insulin of 3-6 month-old (young) WT and Tmem127 KO male mice (n=4 per genotype); D) Glucose tolerance test (GTT) and area under the curve (AUC, inset graph) of 3-6 month-old (young) WT and Tmem127 KO male mice (n=7 and 8 per genotype, respectively); E) Insulin tolerance test (ITT) and AUC (inset) of 3-6 month-old (young) WT and Tmem127 KO male mice (n=7 and 8 per genotype, respectively). Data were analyzed by Student's t-test or two-way ANOVA (in the case of GSIS). Values are expressed as mean +/- s.e.m. *P<0.05; **P<0.01; ***P<0.001. Adult mice were 9-12months of age. Source data are provided as a Source Data file.



Supplementary Fig 4. Tmem127 deletion decreases hepatic gluconeogenesis and increases insulin signaling. A) Relative iWAT mRNA expression of the indicated glucose transporter, glycolysis and gluconeogenesis genes from adult WT and KO mice (n=5 or 8 per genotype, respectively); B) Relative muscle mRNA expression of the indicated glucose transporter, glycolysis and gluconeogenesis genes from adult WT and KO mice (n=7 or 8 per genotype, respectively). Data were analyzed by Student's t-test or two-way ANOVA (in the case of GSIS). Values are expressed as mean +/- s.e.m. *P<0.05; **P<0.01; ***P<0.001. Adult mice were 9-12months of age. Source data are provided as a Source Data file.






Supplementary Fig 5. Tmem127 deletion protects against high-fat diet (HFD)-induced hepatic steatosis and insulin resistance. A) Weight gain relative to start body weight of WT and Tmem127 KO male mice on a 60% kcal fat diet for 16 weeks (n=8 per genotype, starting age 3-5 months); B) Relative lean and fat mass of WT and KO mice after 16 weeks of HFD (n=7 or 8 per genotype, respectively); C) Average weekly calorie intake per body weight of singly housed WT and KO mice on a HFD (n=8 or 7 per genotype, respectively); D) Feed efficiency calculated as the weight gain per kcal food intake, averaged per week) of singly housed WT and KO mice on a HFD (n=8 per genotype); E) Relative iWAT mRNA expression of the indicated fatty acid synthesis, storage and oxidation gene expression from HFD-fed male WT and KO mice (n=8 per genotype, 9-11 mo-old) measured by RT-PCR; F) Relative muscle mRNA expression of the indicated glucose transport and metabolism gene expression from HFD-fed male WT and KO mice (n=7 per genotype, 9-11 mo-old) measured by RT-PCR; G) Relative muscle and iWAT mRNA expression of the indicated lipogenic transcription factor genes from chow or HFD-fed male WT and KO mice (n=8 per genotype, 9-11 mo-old); data were analyzed by Student's t-test. Srebf1, Chrebp values are significantly different per diet, but not per genotype in both tissues. Other values are non-significant. Data were analyzed by Student's t-test and/or ANOVA. Values are expressed as mean +/- s.e.m. *P<0.05; **P<0.01; ***P<0.001; # comparisons between diet; * comparisons between genotype # or *P<0.05; ## or **P<0.01; ### or ***P<0.001. Source data are provided as a Source Data file.

A**HOMA-IR****B****GSIS****C****Liver Triglycerides**


Supplementary Fig 6. Liver-specific *Tmem127*deficient mice show improved glucose metabolism whereas adipose-specific *Tmem127* deficient mice are insulin resistant. A) Homeostatic model assessment -insulin resistance index (HOMA-IR) of adult male Flx, LKO and AKO mice (n= 11 Flx, 14 LKO, 6 AKO), data were analyzed by Student's t-test. Values are expressed as mean +/- s.e.m. *P<0.05; **P<0.01; ***P<0.001. B) Glucose-stimulated insulin secretion (GSIS) of adult Flx, LKO and AKO mice (n=9 Flx, n=6 LKO, n=5 AKO); e); C) Liver triglyceride content of fed Flx, LKO and AKO (n=12, 11 and 7, respectively). Data were analyzed by ANOVA; *p<0.05. Source data are provided as a Source Data file.

A



Liver

**B****C**

Supplementary Fig 7. Adipose-specific *Tmem127* deletion and hepatic insulin signaling. A) Western blot of liver lysates of Flx or AKO chow-fed, adult male (n=3 per genotype), probed with phosphorylated Akt at Ser473 or Thr308 or total Akt; B) Western blot of liver lysates of Flx (n=3); LKO (n=4); AKO (n=3), and one WT and one KO adult male, chow fed samples, probed with Rictor or Tubulin; C) Resting metabolic rate (RMR) calculated from the five lowest values of the adjusted oxygen consumption (VO₂) in mL/hr/g lean body mass in 24h of Flx (n=5) and AKO (n=7) chow-fed, adult male mice. Data were analyzed by two-way ANOVA (n.s., non-significant). Source data are provided as a Source Data file.



Supplementary Fig 8. Characterization of CRISPR-Cas9 mediate-*TMEM127*KO HepG2 cells. Sanger sequencing of a HepG2 clone carrying a heterozygous deletion of exon 2 of the *TMEM127* gene (KO). Guide RNA sequence is indicated with a black bar and PAM sequence is indicated with a blue bar.

A**B**

Supplementary Fig 9. ***Tmem127*mRNA expression of in fat tissues of wild-type adult male mice under chow or high-fat diet (HFD)**, quantified by real time PCR and displayed as relative expression normalized to the *Tfiib* gene: A) results from inguinal white adipose tissue (iWAT; n= chow n=7; HFD n=6; B) results from epididymal white adipose tissue (eWAT; chow n=8; HFD n=7). Data were analyzed by Student's t test; *p<0.05. Source data are provided as a Source Data file.

Supplementary Table 3- Liver TMEM127 mRNA levels and metabolic parameters in patients with fatty liver disease

Variable	Overall P	NAFLD+NASH P	NASH P
Age	0.052	0.058	0.201
BMI	0.019	0.038	0.041
AST	0.798	0.703	0.679
ALT	0.877	0.796	0.379
Insulin	0.005	0.018	0.036
Hba1C	0.019	0.004	0.544
Cholesterol	0.138	0.294	0.904
Triglyceride	0.015	0.075	0.307
INR	0.716	0.323	0.656
Glucose	0.096	0.277	0.934
Weight	0.838	0.693	0.894
HOMA-IR	0.011	0.050	0.203
NAFLD SCORE*	0.349	0.297	0.449

P values (Spearman's Correlation Coefficient) of TMEM127 expression: 'Overall P': all groups combined controls vs. nonalcoholic fatty liver disease (NAFLD) vs. nonalcoholic steatohepatitis (NASH); 'NAFLD + NASH P', combined NAFLD and NASH vs. control; 'NASH P', NASH only vs control; HOMA-IR= homeostatic model assessment of insulin resistance, BMI= body mass index; AST= aspartate amino transferase, ALT= alanine amino transferase; *As reported in Ref (29) Harrison et al. Gut 57, 1441-7 (2008)

Supplementary Table 4. Clinical, metabolic and molecular features of the cohort of patients with fatty acid liver disease

Disease Status	Fibrosis Stage	<i>TMEM127</i> read counts*	T2DM	Insulin (μ IU/L)	HOMA-IR	BMI
Control	0	496.23	Yes	7.90	2.03	36.27
Control	0	147.16	No	9.40	2.20	35.42
Control	0	416.00	Yes	10.80	0.00	31.00
Control	0	491.94	No	15.80	4.41	31.01
Control	0	283.59	No			28.23
Control	0	343.43	No	1.20	0.29	26.38
Control	0	385.07	No	5.40	0.00	
NAFLD	0	490.08	No	69.70	16.69	26.07
NAFLD	0	426.05	No	10.70	3.09	36.77
NAFLD	0	489.00	No	14.70	3.70	24.69
NAFLD	0	530.73	No	19.10	4.53	32.61
NAFLD	0	495.23	No	7.00	1.69	29.99
NAFLD	0	426.00	No	17.40	3.87	33.12
NAFLD	0	359.48	No	11.40	2.42	32.38
NAFLD	0	400.56	No	44.40	10.63	25.60
NAFLD	0	467.38	No	7.60	1.71	26.31
NAFLD	0	444.05	No	18.20	4.45	27.80
NAFLD	0	160.92	No	13.10	3.49	29.66
NAFLD	0	471.48	No	9.50	2.56	29.02
NAFLD	0	280.86	No	14.00	3.28	30.27
NAFLD	0	438.38	No	7.40	1.74	28.41
NAFLD	0	456.75	No	6.30	1.28	30.38
NAFLD	0	438.77	No	23.70	5.79	31.75
NAFLD	0	407.13	No	16.60	3.89	28.17
NAFLD	0	394.36	Yes	21.70	7.34	30.02
NAFLD	0	490.61	No	9.60	2.20	
NAFLD	0	503.62	No	16.40	4.01	
NAFLD	0	438.35	No	9.50	2.58	
NASH	1	495.40	No	15.00	3.93	27.61
NASH	1	451.00	No	26.70	6.13	32.93
NASH	1	524.18	No	116.40	38.23	37.49
NASH	1	556.00	No	52.60	12.08	36.71
NASH	1	469.22	No	27.30	6.40	31.16
NASH	1	550.35	No	41.30	11.63	36.67
NASH	1	500.57	Yes	35.20	13.99	37.27
NASH	1	349.03	No	32.50	9.15	35.44
NASH	1	475.02	Yes	235.20	66.79	36.65
NASH	1	412.65	No	25.70	6.79	27.55
NASH	1	456.46	No	8.70	2.08	34.49
NASH	1	435.18	No	65.70	14.60	32.61
NASH	1	471.56	Yes	4.60	0.99	26.88
NASH	1	410.39	No	8.40	5.08	
NASH	1	500.28	Yes	26.10	15.79	
NASH	1	484.91	No			
NASH	2	510.76	No	17.60	3.69	32.61
NASH	2	494.87	No	13.10	3.11	25.62
NASH	2	500.71	Yes	41.00	10.43	27.53
NASH	2	498.30	Yes	28.90	7.99	
NASH	2	488.55	Yes	24.70	9.51	
NASH	3	437.54	Yes	22.60	13.23	31.35
NASH	3	540.56	No	39.20	10.55	31.47
NASH	3	554.93	Yes	12.70	3.54	37.56

NAFLD=nonalcoholic fatty liver disease, NASH= nonalcoholic steatohepatitis, T2DM= type 2 diabetes, HOMA-IR= homeostatic model assessment of insulin resistance, BMI= body mass index, *normalized read counts

Species	Primer Name	Primer sequence
mouse	Acly_F	GCCAGCGGGAGCACATC
mouse	Acly_R	CTTGCAAGGTGCCACTTCATC
mouse	Acaca_F	GCC TCT TCC TGA CAA ACG AG
mouse	Acaca_R	TGA CTG CCG AAA CAT CTC TG
mouse	Acacb_F	ACTCGCTTGGAGGCAACAG
mouse	Acacb_R	CGCAAGCGATGCCATTGTTG
mouse	Fasn_F	CAG CAG AGT CTA CAG CTA CCT
mouse	Fasn_R	ACC ACC AGA GAC CGT TAT GC
mouse	Scd1_F	CTGACCTGAAAGCCGAGAAG
mouse	Scd1_R	GGCTTGAGCACAGAGTGTGA
mouse	Elov16_F	TGC TGC ATC CAG TTG AAG AC
mouse	Elov16_R	TGC CAT GTT CAT CAC CTT GT
mouse	Cidea_F	GCCTGCAGGAACCTTACAGC
mouse	Cidea_R	TGCTTGAGACTGGGACATA
mouse	Cidec_F	ATGGACTACGCCATGAAGTCT
mouse	Cidec_R	CGGTGCTAACAGCACAGGG
mouse	Ppara_F	AACATCGAGTGTCAATATGTGG
mouse	Ppara_R	CCGAATAGTCGCCAAAGAA
mouse	Cpt1a_F	AGGGCCGATCATGGTTAACAA
mouse	Cpt1a_R	CGTGTGGATGGTGTCTGTC
mouse	Acadm_F	AGGTTCAAGATCGCAATGG
mouse	Acadm_R	ACCTCATGCCATTCTGC
mouse	Cd36_F	ATTCTCATGCCAGTCGGAGA
mouse	Cd36_R	TGGGTTTIGCACATCAAAGA
mouse	Glut2_F	GGCTAATTTCAGGACTGGTT
mouse	Glut2_R	TTTCTTGCCTGACTTCTT
mouse	Gck_F	ATGGCTGTGGACTACAAGGA
mouse	Gck_R	TTCAAGGCCACGGTCCATCT
mouse	G6Pase_F	TGCTGTCACCTTCCCCACAG
mouse	G6Pase_R	TCTCCAAGTCCACAGGAGGT
mouse	Pepck1_F (Pck1)	GACAGCCTGCCAGGGCAGTGA
mouse	Pepck1_R (Pck1)	CTGGCCACATCTCGAGGGTCAG
mouse	Glut4_F	GTGACTGGAACACTGTTCTTA
mouse	Glut4_R	CCAGCCCACCTTGCTTAGTG
mouse	Srebf1_F	GATCAAAGAGGAGCCAGT
mouse	Srebf1_R	TAGATGGTGGCTGCTGAGTG
mouse	Chrebptotal_F	CACTCAGGAATACAGCCTAC
mouse	Chrebptotal_R	ATCTGGTCTTAGGGTCTTCAGG
mouse	Chrebp_F	CGACACTCACCCACCTCTTC
mouse	Chrebp_R	TTGTCAGCCGATCTGTC
mouse	Chrepb_F	TCTGCAGATCGCGTGGAG
mouse	Chrepb_R	CTTGTCCGGCATAGCAAC
mouse	Nr1h2_F	ATAGTGGGTACAGAAGCAGC
mouse	Nr1h2_R	AGGGCAACAGAGTCGAGAGC
mouse	Nr1h3_F	AGGAAGTGTGACTTCGCAA
mouse	Nr1h3_R	CTCTCTTGGCCCTTCAGTT
mouse	Cebpa_F	CAAGAACAGCAACGAGTACCG
mouse	Cebpa_R	GTCACTGGTCAACTCCAGCAC
mouse	Tfibi_F	TGGAGATTGTCACCATGTA
mouse	Tfibi_R	GAATTGCCAAACTCATCAAAACT
mouse	Pdk1_F	GGGGGCTTGTGATTGTAT
mouse	Pdk1_R	ACCTGAATCGGGGGATAAAC
mouse	Pfkp-F	AGGAGGGCAAAAGGAGTT
mouse	Pfkp-R	TTGGCAGAAATCTGGTTC
mouse	Pgd-F	AGACAGGCAGCCACTGAGTT
mouse	Pgd-R	AAAGTCTGGGTTTCGCTCAA
mouse	Gapdh_F	AGGTCGGTGTGAACGGAGTT
mouse	Gapdh_R	TGTAGACCATGTAGTTGAGGTC
mouse	Tmem127_3F	TCGGTATGCCCTTGCTCACATCCT
mouse	Tmem127_4R	ACTCTTATGCTGTTGCTGTCGG
human	ACC1_R	AGTGGGTCACCCCATTGTT
human	ACC1_F	TCTAACAGGAGCTGGAGCC
human	FASN_R	TCTCGACTCTGGCAGCTT
human	FASN_F	GCTCCAGCTCGCTCTC
human	SCD1_R	GCAGCCGAGCTTGTAAAGAG
human	SCD1_F	GTTCCTACCTGGCTTGGGG
human	ELOVL6_R	GTCTCTGACCTTGCACTT
human	ELOVL6_F	CCTGGTCACAAACTGACTGCT
human	SREBF1c_F	AAAATCCGGCCGGCCT
human	SREBF1c_R	GCATGTCTGAAAGTGAA
human	CHREBPb_F	AGCCAGCTCAAGGAGC
human	CHREPBp_R	CTGCTGGCACAGGTTAATGG
human	LXRB_F	CGCTACAACCCAGGAGACAGA
human	LXRB_R	GAATCAGAAGATGGGGTTGA
human	LXRA_F	GAAGAAAATGAAAGCGGCAAGA
human	LXRA_R	ACTCGAAGCGGTCAAGAAA
human	TBP_F	TATAATCCCAAGCGTTGCTGCG
human	TBP_R	AATTGTTGGTGGGTGAGCACAAAGG
human	G6PASE_F (G6PC)	ACTGGCTCAACCTGCTTTA
human	G6PASE_R (G6PC)	CGGAAGTGTGCTGTAGTAGTC
human	TMEM127_F	TCGGTATGCCCTTGCTCACATCCT
human	TMEM127_R	ACTCTTATGCTGTTGCTGTCGG